-
Je něco špatně v tomto záznamu ?
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
A. Chan, S. Delaloge, FA. Holmes, B. Moy, H. Iwata, VJ. Harvey, NJ. Robert, T. Silovski, E. Gokmen, G. von Minckwitz, B. Ejlertsen, SK. Chia, J. Mansi, CH. Barrios, M. Gnant, M. Buyse, I. Gore, J. Smith, G. Harker, N. Masuda, K. Petrakova, AG....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem
NLK
ProQuest Central
od 2000-09-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest)
od 2000-09-01 do Před 2 měsíci
Health & Medicine (ProQuest)
od 2000-09-01 do Před 2 měsíci
Public Health Database (ProQuest)
od 2000-09-01 do Před 2 měsíci
- MeSH
- adjuvantní chemoterapie MeSH
- analýza přežití MeSH
- chinoliny aplikace a dávkování škodlivé účinky MeSH
- dospělí MeSH
- dvojitá slepá metoda MeSH
- internacionalita MeSH
- invazivní růst nádoru patologie MeSH
- Kaplanův-Meierův odhad MeSH
- lidé středního věku MeSH
- lidé MeSH
- mastektomie metody MeSH
- nádory prsu farmakoterapie mortalita patologie chirurgie MeSH
- následné studie MeSH
- přežití bez známek nemoci MeSH
- proporcionální rizikové modely MeSH
- protokoly protinádorové kombinované chemoterapie aplikace a dávkování MeSH
- receptor erbB-2 metabolismus MeSH
- rozvrh dávkování léků MeSH
- senioři MeSH
- staging nádorů MeSH
- trastuzumab aplikace a dávkování škodlivé účinky MeSH
- výsledek terapie MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
BACKGROUND: Neratinib, an irreversible tyrosine-kinase inhibitor of HER1, HER2, and HER4, has clinical activity in patients with HER2-positive metastatic breast cancer. We aimed to investigate the efficacy and safety of 12 months of neratinib after trastuzumab-based adjuvant therapy in patients with early-stage HER2-positive breast cancer. METHODS: We did this multicentre, randomised, double-blind, placebo-controlled, phase 3 trial at 495 centres in Europe, Asia, Australia, New Zealand, and North and South America. Eligible women (aged ≥18 years, or ≥20 years in Japan) had stage 1-3 HER2-positive breast cancer and had completed neoadjuvant and adjuvant trastuzumab therapy up to 2 years before randomisation. Inclusion criteria were amended on Feb 25, 2010, to include patients with stage 2-3 HER2-positive breast cancer who had completed trastuzumab therapy up to 1 year previously. Patients were randomly assigned (1:1) to receive oral neratinib 240 mg per day or matching placebo. The randomisation sequence was generated with permuted blocks stratified by hormone receptor status (hormone receptor-positive [oestrogen or progesterone receptor-positive or both] vs hormone receptor-negative [oestrogen and progesterone receptor-negative]), nodal status (0, 1-3, or ≥4), and trastuzumab adjuvant regimen (sequentially vs concurrently with chemotherapy), then implemented centrally via an interactive voice and web-response system. Patients, investigators, and trial sponsors were masked to treatment allocation. The primary outcome was invasive disease-free survival, as defined in the original protocol, at 2 years after randomisation. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00878709. FINDINGS: Between July 9, 2009, and Oct 24, 2011, we randomly assigned 2840 women to receive neratinib (n=1420) or placebo (n=1420). Median follow-up time was 24 months (IQR 20-25) in the neratinib group and 24 months (22-25) in the placebo group. At 2 year follow-up, 70 invasive disease-free survival events had occurred in patients in the neratinib group versus 109 events in those in the placebo group (stratified hazard ratio 0·67, 95% CI 0·50-0·91; p=0·0091). The 2-year invasive disease-free survival rate was 93·9% (95% CI 92·4-95·2) in the neratinib group and 91·6% (90·0-93·0) in the placebo group. The most common grade 3-4 adverse events in patients in the neratinib group were diarrhoea (grade 3, n=561 [40%] and grade 4, n=1 [<1%] vs grade 3, n=23 [2%] in the placebo group), vomiting (grade 3, n=47 [3%] vs n=5 [<1%]), and nausea (grade 3, n=26 [2%] vs n=2 [<1%]). QT prolongation occurred in 49 (3%) patients given neratinib and 93 (7%) patients given placebo, and decreases in left ventricular ejection fraction (≥grade 2) in 19 (1%) and 15 (1%) patients, respectively. We recorded serious adverse events in 103 (7%) patients in the neratinib group and 85 (6%) patients in the placebo group. Seven (<1%) deaths (four patients in the neratinib group and three patients in the placebo group) unrelated to disease progression occurred after study drug discontinuation. The causes of death in the neratinib group were unknown (n=2), a second primary brain tumour (n=1), and acute myeloid leukaemia (n=1), and in the placebo group were a brain haemorrhage (n=1), myocardial infarction (n=1), and gastric cancer (n=1). None of the deaths were attributed to study treatment in either group. INTERPRETATION: Neratinib for 12 months significantly improved 2-year invasive disease-free survival when given after chemotherapy and trastuzumab-based adjuvant therapy to women with HER2-positive breast cancer. Longer follow-up is needed to ensure that the improvement in breast cancer outcome is maintained. FUNDING: Wyeth, Pfizer, Puma Biotechnology.
Aichi Cancer Center Chikusa ku Nagoya Japan
Alabama Oncology Birmingham AL USA
Auckland Hospital Auckland New Zealand
BC Cancer Agency Vancouver BC Canada
Breast Cancer Research Centre Western Australia and Curtin University Perth WA Australia
Department of Surgery and Comprehensive Cancer Centre Medical University of Vienna Vienna Austria
Ege University Faculty of Medicine Izmir Turkey
Hematology Oncology Associates of Treasure Coast Port Saint Lucie FL USA
Institut Gustave Roussy Villejuif France
Instituto de Investigación Sanitaria Gregorio Marañón Universidad Complutense de Madrid Madrid Spain
Instituto Valenciano de Oncologia València Spain
International Drug Development Institute Louvain la Neuve Belgium
Luisenkrankenhaus German Breast Group Forschungs GmbH Düsseldorf Neu lsenburg Germany
Magna Graecia University Catanzaro Italy
Masaryk Memorial Cancer Institute Brno Czech Republic
Massachusetts General Hospital Cancer Center Boston MA USA
National Hospital Organization Osaka National Hospital Chuou ku Osaka Japan
Northwest Cancer Specialists Vancouver VA USA
Pontifical Catholic University of Rio Grande do Sul School of Medicine Porto Alegre Brazil
Puma Biotechnology Los Angeles CA USA
Rigshospitalet Copenhagen Denmark
South Texas Oncology and Hematology San Antonio TX USA
University Hospital For Tumors University Hospital Center Sestre Milosrdnice Zagreb Croatia
Utah Cancer Specialists Salt Lake City UT USA
Virginia Cancer Specialists The US Oncology Network Fairfax VA USA
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16027670
- 003
- CZ-PrNML
- 005
- 20161031103545.0
- 007
- ta
- 008
- 161005s2016 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S1470-2045(15)00551-3 $2 doi
- 024 7_
- $a 10.1016/S1470-2045(15)00551-3 $2 doi
- 035 __
- $a (PubMed)26874901
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Chan, Arlene $u Breast Cancer Research Centre-Western Australia and Curtin University, Perth, WA, Australia. Electronic address: arlenechan@me.com.
- 245 10
- $a Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial / $c A. Chan, S. Delaloge, FA. Holmes, B. Moy, H. Iwata, VJ. Harvey, NJ. Robert, T. Silovski, E. Gokmen, G. von Minckwitz, B. Ejlertsen, SK. Chia, J. Mansi, CH. Barrios, M. Gnant, M. Buyse, I. Gore, J. Smith, G. Harker, N. Masuda, K. Petrakova, AG. Zotano, N. Iannotti, G. Rodriguez, P. Tassone, A. Wong, R. Bryce, Y. Ye, B. Yao, M. Martin, . ,
- 520 9_
- $a BACKGROUND: Neratinib, an irreversible tyrosine-kinase inhibitor of HER1, HER2, and HER4, has clinical activity in patients with HER2-positive metastatic breast cancer. We aimed to investigate the efficacy and safety of 12 months of neratinib after trastuzumab-based adjuvant therapy in patients with early-stage HER2-positive breast cancer. METHODS: We did this multicentre, randomised, double-blind, placebo-controlled, phase 3 trial at 495 centres in Europe, Asia, Australia, New Zealand, and North and South America. Eligible women (aged ≥18 years, or ≥20 years in Japan) had stage 1-3 HER2-positive breast cancer and had completed neoadjuvant and adjuvant trastuzumab therapy up to 2 years before randomisation. Inclusion criteria were amended on Feb 25, 2010, to include patients with stage 2-3 HER2-positive breast cancer who had completed trastuzumab therapy up to 1 year previously. Patients were randomly assigned (1:1) to receive oral neratinib 240 mg per day or matching placebo. The randomisation sequence was generated with permuted blocks stratified by hormone receptor status (hormone receptor-positive [oestrogen or progesterone receptor-positive or both] vs hormone receptor-negative [oestrogen and progesterone receptor-negative]), nodal status (0, 1-3, or ≥4), and trastuzumab adjuvant regimen (sequentially vs concurrently with chemotherapy), then implemented centrally via an interactive voice and web-response system. Patients, investigators, and trial sponsors were masked to treatment allocation. The primary outcome was invasive disease-free survival, as defined in the original protocol, at 2 years after randomisation. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00878709. FINDINGS: Between July 9, 2009, and Oct 24, 2011, we randomly assigned 2840 women to receive neratinib (n=1420) or placebo (n=1420). Median follow-up time was 24 months (IQR 20-25) in the neratinib group and 24 months (22-25) in the placebo group. At 2 year follow-up, 70 invasive disease-free survival events had occurred in patients in the neratinib group versus 109 events in those in the placebo group (stratified hazard ratio 0·67, 95% CI 0·50-0·91; p=0·0091). The 2-year invasive disease-free survival rate was 93·9% (95% CI 92·4-95·2) in the neratinib group and 91·6% (90·0-93·0) in the placebo group. The most common grade 3-4 adverse events in patients in the neratinib group were diarrhoea (grade 3, n=561 [40%] and grade 4, n=1 [<1%] vs grade 3, n=23 [2%] in the placebo group), vomiting (grade 3, n=47 [3%] vs n=5 [<1%]), and nausea (grade 3, n=26 [2%] vs n=2 [<1%]). QT prolongation occurred in 49 (3%) patients given neratinib and 93 (7%) patients given placebo, and decreases in left ventricular ejection fraction (≥grade 2) in 19 (1%) and 15 (1%) patients, respectively. We recorded serious adverse events in 103 (7%) patients in the neratinib group and 85 (6%) patients in the placebo group. Seven (<1%) deaths (four patients in the neratinib group and three patients in the placebo group) unrelated to disease progression occurred after study drug discontinuation. The causes of death in the neratinib group were unknown (n=2), a second primary brain tumour (n=1), and acute myeloid leukaemia (n=1), and in the placebo group were a brain haemorrhage (n=1), myocardial infarction (n=1), and gastric cancer (n=1). None of the deaths were attributed to study treatment in either group. INTERPRETATION: Neratinib for 12 months significantly improved 2-year invasive disease-free survival when given after chemotherapy and trastuzumab-based adjuvant therapy to women with HER2-positive breast cancer. Longer follow-up is needed to ensure that the improvement in breast cancer outcome is maintained. FUNDING: Wyeth, Pfizer, Puma Biotechnology.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x aplikace a dávkování $7 D000971
- 650 _2
- $a nádory prsu $x farmakoterapie $x mortalita $x patologie $x chirurgie $7 D001943
- 650 _2
- $a adjuvantní chemoterapie $7 D017024
- 650 _2
- $a přežití bez známek nemoci $7 D018572
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 _2
- $a rozvrh dávkování léků $7 D004334
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a internacionalita $7 D038622
- 650 _2
- $a Kaplanův-Meierův odhad $7 D053208
- 650 _2
- $a mastektomie $x metody $7 D008408
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a invazivní růst nádoru $x patologie $7 D009361
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a proporcionální rizikové modely $7 D016016
- 650 _2
- $a chinoliny $x aplikace a dávkování $x škodlivé účinky $7 D011804
- 650 _2
- $a receptor erbB-2 $x metabolismus $7 D018719
- 650 _2
- $a analýza přežití $7 D016019
- 650 _2
- $a trastuzumab $x aplikace a dávkování $x škodlivé účinky $7 D000068878
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a klinické zkoušky, fáze III $7 D017428
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Delaloge, Suzette $u Institut Gustave Roussy, Villejuif, France.
- 700 1_
- $a Holmes, Frankie A $u Texas Oncology, Houston, TX, USA.
- 700 1_
- $a Moy, Beverly $u Massachusetts General Hospital Cancer Center, Boston, MA, USA.
- 700 1_
- $a Iwata, Hiroji $u Aichi Cancer Center, Chikusa-ku, Nagoya, Japan.
- 700 1_
- $a Harvey, Vernon J $u Auckland Hospital, Auckland, New Zealand.
- 700 1_
- $a Robert, Nicholas J $u Virginia Cancer Specialists, The US Oncology Network, Fairfax, VA, USA.
- 700 1_
- $a Silovski, Tajana $u University Hospital For Tumors, University Hospital Center "Sestre Milosrdnice", Zagreb, Croatia.
- 700 1_
- $a Gokmen, Erhan $u Ege University Faculty of Medicine, Izmir, Turkey.
- 700 1_
- $a von Minckwitz, Gunter $u Luisenkrankenhaus, German Breast Group Forschungs GmbH, Düsseldorf, Neu-lsenburg, Germany.
- 700 1_
- $a Ejlertsen, Bent $u Rigshospitalet, Copenhagen, Denmark.
- 700 1_
- $a Chia, Stephen K L $u BC Cancer Agency, Vancouver, BC, Canada.
- 700 1_
- $a Mansi, Janine $u Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London, UK.
- 700 1_
- $a Barrios, Carlos H $u Pontifical Catholic University of Rio Grande do Sul School of Medicine, Porto Alegre, Brazil.
- 700 1_
- $a Gnant, Michael $u Department of Surgery and Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria.
- 700 1_
- $a Buyse, Marc $u International Drug Development Institute (IDDI), Louvain-la-Neuve, Belgium.
- 700 1_
- $a Gore, Ira $u Alabama Oncology, Birmingham, AL, USA.
- 700 1_
- $a Smith, John $u Northwest Cancer Specialists, Vancouver, VA, USA.
- 700 1_
- $a Harker, Graydon $u Utah Cancer Specialists, Salt Lake City, UT, USA.
- 700 1_
- $a Masuda, Norikazu $u National Hospital Organization Osaka National Hospital, Chuou-ku, Osaka, Japan.
- 700 1_
- $a Petrakova, Katarina $u Masaryk Memorial Cancer Institute, Brno, Czech Republic.
- 700 1_
- $a Zotano, Angel Guerrero $u Instituto Valenciano de Oncologia, València, Spain.
- 700 1_
- $a Iannotti, Nicholas $u Hematology Oncology Associates of Treasure Coast, Port Saint Lucie, FL, USA.
- 700 1_
- $a Rodriguez, Gladys $u South Texas Oncology and Hematology, San Antonio, TX, USA.
- 700 1_
- $a Tassone, Pierfrancesco $u Magna Graecia University, Catanzaro, Italy.
- 700 1_
- $a Wong, Alvin $u Puma Biotechnology, Los Angeles, CA, USA.
- 700 1_
- $a Bryce, Richard $u Puma Biotechnology, Los Angeles, CA, USA.
- 700 1_
- $a Ye, Yining $u Puma Biotechnology, Los Angeles, CA, USA.
- 700 1_
- $a Yao, Bin $u Puma Biotechnology, Los Angeles, CA, USA.
- 700 1_
- $a Martin, Miguel $u Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain.
- 700 1_
- $a ,
- 773 0_
- $w MED00011558 $t The Lancet. Oncology $x 1474-5488 $g Roč. 17, č. 3 (2016), s. 367-77
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26874901 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20161005 $b ABA008
- 991 __
- $a 20161031104006 $b ABA008
- 999 __
- $a ok $b bmc $g 1165984 $s 952300
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 17 $c 3 $d 367-77 $e 20160210 $i 1474-5488 $m Lancet oncology $n Lancet Oncol. $x MED00011558
- LZP __
- $a Pubmed-20161005
